Latest News

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.
Rintatolimod/Durvalumab Dose Appears Tolerable in Pancreatic Cancer

April 30th 2024

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.
FOLFIRI Plus ICIs Display Anti-Tumor Activity in Gastric/GEJ Cancer

April 30th 2024

Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.
Trastuzumab-strf Gets FDA Approval in Overexpressing Breast and Gastric Cancers

April 29th 2024

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.
ASCO Guideline Issues Updated Systemic Therapy Recommendations in HCC

April 26th 2024

ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC

April 23rd 2024